Actively Recruiting
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
Led by Dana-Farber Cancer Institute · Updated on 2025-06-12
300
Participants Needed
8
Research Sites
624 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
C
Charles H. Hood Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.
CONDITIONS
Official Title
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age: birth to less than 30 years old
- Diagnosis of acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome, or myeloproliferative syndromes, either newly diagnosed or relapsed/refractory
- Histologic confirmation of leukemia, myelodysplastic syndrome, or myeloproliferative syndrome at diagnosis or recurrence
- Sufficient sample available for genomic profiling or planned bone marrow aspirate or blood draw expected to provide minimum specimen for testing
You will not qualify if you...
- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence
- Bone marrow evaluations not planned for clinical care
- Peripheral blast percentage less than 20%
- Clinical blood draw not planned
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106
Actively Recruiting
2
Maine Medical Center
Portland, Maine, United States, 04102
Actively Recruiting
3
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Active, Not Recruiting
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Active, Not Recruiting
5
Dartmouth-Hitchcock
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
6
Albany Medical Center
Albany, New York, United States, 12208
Actively Recruiting
7
Lifespan Cancer Institute
Providence, Rhode Island, United States, 02903
Actively Recruiting
8
University of Vermont Medical Center
Burlington, Vermont, United States, 05401
Actively Recruiting
Research Team
Y
Yana Pikman, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here